Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
Gynecologic Oncology|January 15, 1999
A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancerR W Naumann, R D Alvarez, G A Omura, et al.
Gynecologic Oncology|September 10, 1999
A comparison of treatment strategies for endometrial adenocarcinoma: analysis of financial impactM N Barnes, P Y Roland, M Straughn, et al.
Obstetrics and Gynecology|August 1, 1994
Appraisal of the modalities used to evaluate an initial abnormal Papanicolaou smearR V Higgins, J B Hall, J A McGee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1995
Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovirM E Rosenfeld, M Feng, S I Michael, et al.
Infection and Immunity|November 24, 1998
Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humansA Kantele, M Häkkinen, Z Moldoveanu, et al.
Southern Medical Journal|October 1, 1996
Treatment of cervical dysplasia with large loop excision of the transformation zone: is endocervical curettage necessary?R W Naumann, M A Crispens, R D Alvarez, et al.
Gynecologic Oncology|April 1, 1990
Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancerM E Potter, R D Alvarez, F L Gay, et al.
Gynecologic Oncology|October 1, 1995
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibodyJ Deshane, G Cabrera, J E Grim, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 1, 1996
Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinomaM E Rosenfeld, M Wang, G P Siegal, et al.
Gynecologic Oncology|January 15, 1999
A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group studyL G Feun, J A Blessing, F J Major, et al.
Pageof 10